153 related articles for article (PubMed ID: 31526466)
1. National cost savings from an ambulatory program for low-risk febrile neutropenia patients in Australia.
Tew M; Forster D; Teh BW; Dalziel K
Aust Health Rev; 2019 Oct; 43(5):549-555. PubMed ID: 31526466
[TBL] [Abstract][Full Text] [Related]
2. Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center.
Nguyen M; Jacobson T; Torres J; Wann A
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1345. PubMed ID: 33635593
[TBL] [Abstract][Full Text] [Related]
3. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
[TBL] [Abstract][Full Text] [Related]
4. Home-based care of low-risk febrile neutropenia in children-an implementation study in a tertiary paediatric hospital.
Haeusler GM; Gaynor L; Teh B; Babl FE; Orme LM; Segal A; Mechinaud F; Bryant PA; Phillips B; Lourenco RA; Slavin MA; Thursky KA
Support Care Cancer; 2021 Mar; 29(3):1609-1617. PubMed ID: 32740894
[TBL] [Abstract][Full Text] [Related]
5. An analysis of the resource use and costs of febrile neutropenia events in pediatric cancer patients in Australia.
Vargas C; Haeusler GM; Slavin MA; Babl FE; Mechinaud F; Phillips R; Thursky K; Lourenco RA;
Pediatr Blood Cancer; 2023 Nov; 70(11):e30633. PubMed ID: 37592047
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia.
Dulisse B; Li X; Gayle JA; Barron RL; Ernst FR; Rothman KJ; Legg JC; Kaye JA
J Med Econ; 2013; 16(6):720-35. PubMed ID: 23452298
[TBL] [Abstract][Full Text] [Related]
8. Direct costs associated with febrile neutropenia in inpatients with hematological diseases in Singapore.
Zhou YP; Jin J; Ding Y; Chee YL; Koh LP; Chng WJ; Chan DS; Hsu LY
Support Care Cancer; 2014 Jun; 22(6):1447-51. PubMed ID: 24287505
[TBL] [Abstract][Full Text] [Related]
9. Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre.
Teh BW; Brown C; Joyce T; Worth LJ; Slavin MA; Thursky KA
Support Care Cancer; 2018 Mar; 26(3):997-1003. PubMed ID: 29018966
[TBL] [Abstract][Full Text] [Related]
10. Cost savings vary by length of stay for inpatients receiving palliative care consultation services.
Starks H; Wang S; Farber S; Owens DA; Curtis JR
J Palliat Med; 2013 Oct; 16(10):1215-20. PubMed ID: 24003991
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of home-based care of febrile neutropenia in children with cancer.
Tew M; De Abreu Lourenco R; Gordon JR; Thursky KA; Slavin MA; Babl FA; Orme L; Bryant PA; Teh BW; Dalziel K; Haeusler GM
Pediatr Blood Cancer; 2022 Jul; 69(7):e29469. PubMed ID: 34854550
[TBL] [Abstract][Full Text] [Related]
12. Costs associated with febrile neutropenia in solid tumor and lymphoma patients - an observational study in Singapore.
Wang XJ; Wong M; Hsu LY; Chan A
BMC Health Serv Res; 2014 Sep; 14():434. PubMed ID: 25252614
[TBL] [Abstract][Full Text] [Related]
13. The cost of the inpatient management of febrile neutropenia in cancer patients--a micro-costing study in the Irish healthcare setting.
O'Brien C; Fogarty E; Walsh C; Dempsey O; Barry M; Kennedy MJ; McCullagh L
Eur J Cancer Care (Engl); 2015; 24(1):125-32. PubMed ID: 24472035
[TBL] [Abstract][Full Text] [Related]
14. A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment.
Lingaratnam S; Worth LJ; Slavin MA; Bennett CA; Kirsa SW; Seymour JF; Dalton A; Koczwara B; Prince HM; O'Reilly M; Mileshkin L; Szer J; Thursky KA
Aust Health Rev; 2011 Nov; 35(4):491-500. PubMed ID: 22126955
[TBL] [Abstract][Full Text] [Related]
15. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting.
Ektare V; Khachatryan A; Xue M; Dunne M; Johnson K; Stephens J
J Med Econ; 2015; 18(12):1092-101. PubMed ID: 26368787
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Use of Filgrastim for Established Febrile Neutropenia Is Cost Effective Among Patients With Solid Tumors and Lymphomas.
Wang XJ; Tong WX; Chan A
Clin Ther; 2017 Jun; 39(6):1161-1170. PubMed ID: 28554533
[TBL] [Abstract][Full Text] [Related]
17. Management of Febrile Neutropenias in Adolescents and Young Adults: A Cost-Minimization Analysis Between Adult Versus Pediatric Units.
Penel-Page M; Marec-Bérard P; Morelle M; Bertrand A; Riberon C; Boyle H; Perrier L
J Adolesc Young Adult Oncol; 2017 Dec; 6(4):542-550. PubMed ID: 28678005
[TBL] [Abstract][Full Text] [Related]
18. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
